NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbPRNewsWire • 05/22/24
Top Wall Street Strategist Sees 500 Point S&P 500 Drop – Buy 6 Passive Income Dividend Stocks Now24/7 Wall Street • 05/21/24
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible CampaignBusiness Wire • 05/21/24
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)Business Wire • 05/21/24
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque PsoriasisBusiness Wire • 05/16/24
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular LymphomaBusiness Wire • 05/16/24
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 TranscriptSeeking Alpha • 05/15/24
Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)Seeking Alpha • 05/13/24
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)Business Wire • 05/06/24
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with MicrosatelliteBusiness Wire • 05/06/24
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?The Motley Fool • 05/03/24